184 related articles for article (PubMed ID: 22286675)
21. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.
Fiori B; Posteraro B; Torelli R; Tumbarello M; Perlin DS; Fadda G; Sanguinetti M
Antimicrob Agents Chemother; 2011 Jun; 55(6):3031-5. PubMed ID: 21422210
[TBL] [Abstract][Full Text] [Related]
22. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
23. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins.
Martos AI; Romero A; González MT; González A; Serrano C; Castro C; Pemán J; Cantón E; Martín-Mazuelos E
Med Mycol; 2010 Sep; 48(6):858-61. PubMed ID: 20144131
[TBL] [Abstract][Full Text] [Related]
26. Echinocandins - structure, mechanism of action and use in antifungal therapy.
Szymański M; Chmielewska S; Czyżewska U; Malinowska M; Tylicki A
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):876-894. PubMed ID: 35296203
[TBL] [Abstract][Full Text] [Related]
27. Echinocandins in antifungal pharmacotherapy.
Patil A; Majumdar S
J Pharm Pharmacol; 2017 Dec; 69(12):1635-1660. PubMed ID: 28744860
[TBL] [Abstract][Full Text] [Related]
28. Echinocandins: Their role in the management of
Swaminathan S; Kamat S; Pinto NA
Indian J Med Microbiol; 2018; 36(1):87-92. PubMed ID: 29735833
[TBL] [Abstract][Full Text] [Related]
29. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
30. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
31. Anidulafungin: when and how? The clinician's view.
George J; Reboli AC
Mycoses; 2012 Jan; 55(1):36-44. PubMed ID: 21668526
[TBL] [Abstract][Full Text] [Related]
32. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
Scott LJ
Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
[TBL] [Abstract][Full Text] [Related]
33. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
34. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
Montejo M; Quindós G
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
[TBL] [Abstract][Full Text] [Related]
35. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
36. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
37. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
[TBL] [Abstract][Full Text] [Related]
38. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
39. [Micafungin: experimental therapy of fungal infections in animal models].
Javier Pastor F; Guarro J
Rev Iberoam Micol; 2009 Mar; 26(1):42-8. PubMed ID: 19463276
[TBL] [Abstract][Full Text] [Related]
40. [In vitro antifungal activity of anidulafungin].
Quindós G; Eraso E
Rev Iberoam Micol; 2008 Jun; 25(2):83-91. PubMed ID: 18473502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
